Esperion Therapeutics Inc. (ESPR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Esperion Therapeutics Inc... (ESPR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.26

-0.02 (-0.88%)

At close: Jan 14, 2025, 3:59 PM

2.23

-1.30%

Pre-market Jan 15, 2025, 04:02 AM EST

undefined% (undefined)

Bid	2.24
Market Cap	445.18M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.67
PE Ratio (ttm)	-3.37
Forward PE	n/a
Analyst	Buy

Ask	2.31
Volume	4,123,279
Avg. Volume (20D)	5,889,881
Open	2.30
Previous Close	2.28
Day's Range	2.23 - 2.40
52-Week Range	1.58 - 3.94
Beta	undefined

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jun 26, 2013

Employees 240

Stock Exchange NASDAQ

Ticker Symbol ESPR

Website https://www.esperion.com

Analyst Forecast

According to 5 analyst ratings, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 121.30% from the latest price.

Buy 60.00%

Hold 20.00%

Sell 20.00%

Stock Forecasts

Next Earnings Release

Esperion Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $63.06M, reflecting a 95.53% YoY growth and earnings per share of -0.13, making a -74.00% decrease YoY.

Why Price Moved

4 weeks ago · Source

+5.58%

Esperion Therapeutics shares are trading higher af... Unlock content with Pro Subscription

1 month ago · Source

+10.71%

Esperion Therapeutics shares are trading higher after the company announced it has filed a new drug submission to Health Canada for Nexletol and Nexlizet.

News

1 month ago · seekingalpha.com

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical ...

1 month ago · zacks.com

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.

2 months ago · seekingalpha.com

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization ...

2 months ago · zacks.com

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates.

2 months ago · zacks.com

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago.

2 months ago · zacks.com

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.